On the Record · Acadia Pharmaceuticals
Acadia Pharmaceuticals competitors, on the record
The companies Acadia Pharmaceuticals itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Acadia Pharmaceuticals names
| Company | Named in |
|---|---|
| Unravel Bio | 2025 |
In its own words
Unravel Bio
Word for word“Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of Rett syndrome, including Unravel Bio and Vanderbilt University Medical Center, which are jointly conducting an early-stage study with vorinostat (RVL-001).” 10-K for 2025
Read from Acadia Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.